Ocuphire Pharma Inc SEC Filings

Opus Genetics, Inc. reported license and collaboration revenue of $2.882 million for the quarter and $7.252 million for the six months, up from $1.112 million and $2.823 million a year earlier. Operating expenses rose to $11.8 million in the quarter (research and development $6.0 million; general and administrative $5.8 million), producing a net loss of $7.42 million for the quarter and $15.614 million for the six-month period, with basic and diluted loss per share of $(0.12) and $(0.32), respectively.

The balance sheet shows $32.4 million in cash and cash equivalents and total assets of $38.7 million. Total liabilities were $21.2 million, including $11.8 million of warrant liabilities recorded in connection with March 2025 financings that produced combined gross proceeds of approximately $21.5 million. The Company had 59,908,055 shares outstanding as of the reported count and states its current cash is sufficient to fund planned expenditures for at least twelve months. The filing discloses sizeable potential milestone obligations under acquired licenses (including maximums of $111.7 million, $76.4 million and $93.5 million for certain agreements) that were not recorded because they were not deemed probable.

Opus Genetics, Inc. reported that on August 13, 2025 it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this Current Report and the company also furnished a Cover Page Interactive Data File (Inline XBRL) as Exhibit 104.1. The filing states the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and therefore is not subject to Section 18 of the Exchange Act or incorporated by reference except by specific reference in a later filing. The report shows Opus Genetics is a Delaware corporation and lists its common stock trading under the ticker IRD on Nasdaq. The document is signed by Dr. George Magrath, Chief Executive Officer.

Opus Genetics, Inc. Schedule 13G disclosures show that a group of affiliated Bios entities and related parties report shared beneficial ownership of 3,683,429 shares, representing 6.2% of the common stock (based on 59,661,197 shares outstanding as of May 12, 2025). The holdings are reported as shared voting and dispositive power; individual Bios Fund III vehicles report smaller direct stakes (for example, Bios Fund III QP, LP reports 2,801,953 shares or 4.7%). The filing identifies the security as Common Stock, par $0.0001, CUSIP 00887A204.

The Schedule includes standard confirmations of passive intent: the filers certify the securities were not acquired to change or influence issuer control. Contact and organizational details are provided for the issuer (principal office in Durham, NC) and the filers (principal office in Fort Worth, TX), and related organizational relationships among the Bios and Cavu entities are disclosed to explain shared power.

Opus Genetics (Nasdaq:OCUP) filed a Form 8-K disclosing topline results from VEGA-3, its second pivotal Phase 3 trial of Phentolamine Ophthalmic Solution 0.75 % for presbyopia. Numerical efficacy and safety data were not included, but management deemed the readout material and will host a webcast on June 26, 2025 at 8:00 a.m. ET to discuss the findings and give a corporate update.

The filing reiterates prior guidance that cash on hand should fund operations into 2H FY 2026, suggesting no immediate financing need. Exhibit 99.1 contains the full press release; no new contracts, financings, or governance changes were reported. Forward-looking-statement disclaimers reference previously disclosed risk factors.